IL-2R-BETA-GAMMA BINDING COMPOUNDS

1 . An IL-2Rβγc binding compound, wherein the IL-2Rβγc binding compound comprises an IL-2Rβγc ligand, wherein the IL-2Rβγc ligand comprises:

a ligand linker;

an IL-2Rγc ligand bound to the ligand linker, wherein the IL-2Rγc ligand comprises any one of SEQ ID NO: 944-1028, 1032, 1034, 1042, 1044, 1051-1060, and 1601-1613; and

an IL-2Rβ ligand bound to the ligand linker, wherein the IL-2Rβ ligand comprises any one of Formula (1) (SEQ ID NO: 805), Formula (1a) (SEQ ID NO: 806), Formula (1b) (SEQ ID NO: 807), Formula (1c) (SEQ ID NO: 808), and Formula (1d) (SEQ ID NO: 809):

-X 211 -X 212 -X 213 -X 214 -C-X 215 -X 216 -X 217 -X 218 -X 219 -X 220 -X 221 -X 222 -C-X 223 -X 224 -X 225   (1)

-X 212 -X 213 -X 214 -C-X 215 -X 216 -X 217 -X 218 -X 219 -X 220 -X 221 -X 222 -C-X 223 -X 224 -  (1a)

-X 213 -X 214 -C-X 215 -X 216 -X 217 -X 218 -X 219 -X 220 -X 221 -X 222 -C-X 223 -X 224 -  (1b)

-X 24 -C-X 215 -X 216 -X 127 -X 218 -X 219 -X 220 -X 221 -X 222 -C-X 223 -  (1c)

-C-X 215 -X 216 -X 217 -X 218 -X 219 -X 220 -X 221 -X 222 -C-  (1d)

wherein,

X 211 is selected from an amino acid;

X 212 is selected from F, H, W, and Y;

X 213 is selected from F, H, I, L, M, V, W, and Y;

X 214 is P;

X 215 is selected from F, H, W, and Y;

X 216 is selected from F, I, L, M, V, W, and Y;

X 217 is A;

X 218 is selected from H, K, N, Q, R, S, T, and Y;

X 219 is selected from F, I, L, M, V, W, and Y;

X 220 is G;

X 221 is selected from D, E, H, N, Q, S, T, and Y;

X 222 is L;

X 223 is D;

X 224 is selected from F, I, L, M, V, W, and Y; and

X 225 is selected from D and E.

2 . The IL-2Rβγc binding compound of claim 1 , wherein the Rγc ligand comprises SEQ ID NO: 965.

3 . The IL-2Rβγc binding compound of claim 1 , wherein X 211 is selected from H, K, and R.

4 . The IL-2Rβγc binding compound of claim 1 , wherein X 212 is W.

5 . The IL-2Rβγc binding compound of claim 1 , wherein X 213 is selected from L and Y.

6 . The IL-2Rβγc binding compound of claim 1 , wherein X 215 is W.

7 . The IL-2Rβγc binding compound of claim 1 , wherein X 216 is M.

8 . The IL-2Rβγc binding compound of claim 1 , wherein X 218 is selected from K, Q, and R.

9 . The IL-2Rβγc binding compound of claim 1 , wherein X 219 is L.

10 . The IL-2Rβγc binding compound of claim 1 , wherein X 221 is E.

11 . The IL-2Rβγc binding compound of claim 1 , wherein X 224 is L.

12 . The IL-2Rβγc binding compound of claim 1 , wherein,

X 211 is selected from H, K, and R;

X 212 is W;

X 213 is Y;

X 214 is P;

X 215 is W;

X 216 is M;

X 217 is A;

X 218 is selected N and Q;

X 219 is selected from L and V;

X 220 is G;

X 221 is selected from E, D, and Q;

X 222 is L;

X 223 is D;

X 224 is selected from L and M; and

X 225 is selected from D and E.

13 . The IL-2Rβγc binding compound of claim 1 , wherein,

X 211 is selected from H and R;

X 212 is selected from F and W;

X 213 is selected from F, L, W, and Y;

X 214 is P;

X 215 is selected from W and Y;

X 216 is selected from F, I, L, M, and V;

X 217 is A;

X 218 is selected H, K, N, Q, and R;

X 219 is selected from L and V;

X 220 is G;

X 221 is selected from D, E, and Q;

X 222 is L;

X 223 is D;

X 224 is selected L, M, and V; and

X 225 is selected from D and E.

14 . The IL-2Rβγc binding compound of claim 1 , wherein,

X 211 is selected from H and R;

X 22 is W;

X 213 is selected from P and Y;

X 214 is P;

X 215 is W;

X 216 is M;

X 217 is A;

X 218 is selected from K, Q and R;

X 219 is L;

X 220 is G;

X 221 is Q;

X 222 is L;

X 223 is D;

X 224 is L; and

X 225 is selected from D and E.

15 . The IL-2Rβγc binding compound of claim 1 , wherein, the IL-2Rβ ligand comprises any one of SEQ ID NO: 810-903.

16 . The IL-2Rβγc binding compound of claim 1 , wherein the ligand linker comprises (G) n (SEQ ID NO: 9380), (GS) n (SEQ ID NO: 9381), (GGS) n (SEQ ID NO: 9382), (GGGS) n (SEQ ID NO: 9383), (GGGGS) n (SEQ ID NO: 9384), or a combination of any of the foregoing, wherein n is an integer from 1 to 20.

17 . The IL-2Rβγc binding compound of claim 1 , wherein the ligand linker comprises (GGGGS) (SEQ ID NO: 9395), (GGGGS)2 (SEQ ID NO: 9396), (GGGGS)3 (SEQ ID NO: 9397), (GGGGS)4 (SEQ ID NO: 9398), (GG) (SEQ ID NO: 9399), (GGG) (SEQ ID NO: 9400), (GGGGG) (SEQ ID NO: 9401), (GGS) (SEQ ID NO: 9402), (GGGS) (SEQ ID NO: 9403), (GGGGSGG) (SEQ ID NO: 9404), (GGS)2 (SEQ ID NO: 9405), (G)5 (SEQ ID NO: 9406), or (GS)10 (SEQ ID NO: 9407).

18 . The IL-2Rβγc binding compound of claim 1 , wherein the ligand linker comprises (PA)n, wherein n is an integer from 1 to 20.

19 . The IL-2Rβγc binding compound of claim 1 , wherein the IL-2Rβγc binding compound comprises a construct partner, wherein the IL-2Rβγc ligand is bound to the construct partner.

20 . The IL-2Rβγc binding compound of claim 19 , wherein in the IL-2Rβγc ligand is bound to the construct partner through a construct linker.

21 . The IL-2Rβγc binding compound of claim 20 , wherein the construct linker comprises a peptidyl construct linker.

22 . The IL-2Rβγc binding compound of claim 21 , wherein the peptidyl construct linker is selected from any one of SEQ ID NO: 9380-9401 and 9420-9425, wherein n is an integer from 1 to 30.

23 . The IL-2Rβγc binding compound of claim 22 , wherein the construct partner is selected from a polymer, a polypeptide, an Fc-fragment, an immunoglobulin fragment, an antibody, a viral surface antigen or a virus-like particle, a cytokine, and a recombinant fusion protein.

24 . The IL-2Rβγc binding compound of claim 23 , wherein the construct partner is selected from a polyethylene glycol, a hIgG-Fc recombinant fusion protein, and a hIgG1-Fc recombinant fusion protein.

25 . The IL-2Rβγc binding compound of claim 19 , wherein the construct partner comprises an antibody and the antibody is directed to a tumor antigen.

26 . The IL-2Rβγc binding compound of claim 19 , wherein the construct partner comprises a cell-targeting moiety.

27 . The IL-2Rβγc binding compound of claim 26 , wherein cell-targeting moiety comprises a tumor-targeting moiety, an immune cell-targeting moiety, or a combination thereof.

28 . A pharmaceutical composition comprising the IL-2Rβγc binding compound of claim 1 .